Market Newsdesk

November 14, 2020 4:15 pm

Hot Wheels®Legends Tour Winner Announced During Finale Event at Jay Leno’s Garage: Custom Car Joins Hot Wheels®Collection as 1:64-scale Die-Cast Vehicle

Hot Wheels®Legends Tour Winner Announced During Finale Event at Jay Leno’s Garage: Custom Car Joins Hot Wheels®Collection as 1:64-scale Die-Cast Vehicle

The 1970 Pontiac Trans Am is named the winner of the Hot Wheels Legends Tour, the world’s largest international traveling car show
The global search for the next Hot Wheels die-cast culminated at the iconic Jay Leno’s Garage after a historic series of virtual car shows

EL SEGUNDO, Calif.–(BUSINESS WIRE)–
Mattel (NASDAQ: MAT) announced today the winner of the 2020 Hot Wheels Legends Tour. The 1970 Pontiac Trans Am custom car, built by Riley Stair of Sacramento, will be inducted into the Hot Wheels Garage of Legends and will join the Hot Wheels collection as a 1:64 scale die-cast. The 1970 Pontiac Trans Am is the third fan’s car to become a Hot Wheels die-cast and will hit store shelves worldwide in 2021. The announcement was made during the Hot Wheels Legends Tour Finale event by Ted Wu, Vice President of Global Design for Vehicles at Mattel.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201114005121/en/

The 1970 Pontiac Trans Am is named the winner of the Hot Wheels Legends Tour, the world’s largest international traveling car show (Photo: Business Wire)

The final stop was live-streamed from Jay Leno’s Garage and co-hosted by Jay Leno and motorsports ambassador Jarod DeAnda. Viewers tuned into Jay Leno’s Garage YouTube Page and Hot Wheels’ Facebook Page to see the winner determined by Hot Wheels designers and car-loving celebrity judges Jay Leno, Snoop Dogg, Gabriel ‘Fluffy’ Iglesias and Brionna Lynch. Special guests including 007 driver Ben Collins, Paxton Booth and NASCAR driver Tony Stewart also participated in the event.

Riley Stair’s build was chosen from thousands of cars entered in the Hot Wheels Legends Tour, which had 14 stops throughout Europe, LATAM, Asia and North America. While all finalists who competed at the global finale event embodied Hot Wheels high standards or performance and design, the winning custom build was selected for its true representation of the Hot Wheels garage spirit.

“By going virtual, the third year of the Hot Wheels Legends Tour demonstrated tremendous growth, engaging over 10 million fans from around the world,” said Ted Wu, Vice President, Global Head of Design for Vehicles, Mattel. “With more vehicle entries this year than ever before, we know we found a special build that embodies the Hot Wheels challenger spirit with the 1970 Pontiac Trans Am. You see the vehicle and instantly know it is meant to be a Hot Wheels with the unique frame, engine, and purpose-driven build.”

The 1970 Pontiac Trans Am is a one of a kind race car engineered by Riley Stair on the side of his parents’ house. Revving up to 10,000 RPM, the vehicles motor is entirely custom built, and the foundation for the engine is a 400-cubic inch LS V8.

“To have my car immortalized as a Hot Wheels die-cast for car lovers of all ages to enjoy means the world to me,” said Legends Tour Winner Riley Stair. “To think that my car in a 1:64 scale could make a lasting impression for a young kid who loves cars, as Hot Wheels have for so many of us, is a dream come true. I can’t wait to see my nephew Noah pushing my car around the living room!”

A team of judges, including Hot Wheels designers, celebrities and automotive influencers, chose the Legends Tour winner for its authenticity, originality and garage spirit. The Legends Tour winner’s life-size car and die-cast version will also join the Hot Wheels Garage of Legends, a collection of one-of-a-kind cars immortalized as Hot Wheels die-casts that meet the brand’s high benchmarks of style and performance.

The Hot Wheels Legends Tour Finale event was made possible in partnership with Mobil 1, Walmart, Ford, American Pinball, Hagerty and Horizon Brands. To learn more about the Hot Wheels Legends Tour visit https://hotwheels.mattel.com/explore/en/legends-tour# and follow #HotWheelsLegends.

About Mattel

Mattel is a leading global toy company and owner of one of the strongest catalogs of children’s and family entertainment franchises in the world. We create innovative products and experiences that inspire, entertain and develop children through play. We engage consumers through our portfolio of iconic brands, including Barbie®, Hot Wheels®, Fisher-Price®, American Girl®, Thomas & Friends™, UNO® and MEGA®, as well as other popular intellectual properties that we own or license in partnership with global entertainment companies. Our offerings include film and television content, gaming, music and live events. We operate in 35 locations and our products are available in more than 150 countries in collaboration with the world’s leading retail and e-commerce companies. Since its founding in 1945, Mattel is proud to be a trusted partner in empowering children to explore the wonder of childhood and reach their full potential.

MAT-CORP

View source version on businesswire.com: https://www.businesswire.com/news/home/20201114005121/en/

Scott Shaffstall

Mattel Global Communications

[email protected]

310-252-3610

Michelle Neumayr

Mattel Global Communications

[email protected]

650-215-8804

Natalie Hamlin

Weber Shandwick

[email protected]

276-732-1464

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: Retail Automotive Consumer Department Stores Performance & Special Interest Children Specialty

MEDIA:

Photo

The 1970 Pontiac Trans Am is named the winner of the Hot Wheels Legends Tour, the world’s largest international traveling car show (Photo: Business Wire)

November 14, 2020 3:43 pm

ROSEN, A TOP RANKED LAW FIRM, Reminds Evolus, Inc. Investors of Important December 15 Deadline in Securities Class Action – EOLS

PR Newswire

NEW YORK, Nov. 14, 2020 /PRNewswire/ — Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Evolus, Inc. (NASDAQ: EOLS) between February 1, 2019 and July 6, 2020, inclusive (the “Class Period”), of the important December 15, 2020 lead plaintiff deadline in the securities class action. The lawsuit seeks to recover damages for Evolus investors under the federal securities laws.

To join the Evolus class action, go to http://www.rosenlegal.com/cases-register-1954.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.

According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) the real source of botulinum toxin bacterial strain as well as the manufacturing processes used to develop Jeuveau™ originated with and were misappropriated from Medytox; (2) sufficient evidentiary support existed for the allegations that Evolus misappropriated certain trade secrets relating to the botulin toxin strain and the manufacturing processes for the development of Jeuveau™; (3) as a result, Evolus faced a real threat of regulatory and/or court action, prohibiting the import, marketing, and sale of Jeuveau™; (4) which in turn seriously threatened Evolus’ ability to commercialize Jeuveau™ in the United States and generate revenue; and (5) any revenues generated from the sale of Jeuveau™ were based on Evolus’ unlawful activities, including the misappropriation of trade secrets and secret manufacturing processes belonging to Allergan and Medytox. When the true details entered the market, the lawsuit claims that investors suffered damages.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than December 15, 2020. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://www.rosenlegal.com/cases-register-1954.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at [email protected] or [email protected].

NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY RETAIN COUNSEL OF YOUR CHOICE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. AN INVESTOR’S ABILITY TO SHARE IN ANY POTENTIAL FUTURE RECOVERY IS NOT DEPENDENT UPON SERVING AS LEAD PLAINTIFF.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 3 each year since 2013. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm’s attorneys are ranked and recognized by numerous independent and respected sources. Rosen Law Firm has secured hundreds of millions of dollars for investors. Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

      Laurence Rosen, Esq.
      Phillip Kim, Esq.
      The Rosen Law Firm, P.A.
      275 Madison Avenue, 40th Floor
      New York, NY 10016
      Tel: (212) 686-1060
      Toll Free: (866) 767-3653
      Fax: (212) 202-3827
      [email protected]
      [email protected]
      [email protected]
      www.rosenlegal.com

View original content:http://www.prnewswire.com/news-releases/rosen-a-top-ranked-law-firm-reminds-evolus-inc-investors-of-important-december-15-deadline-in-securities-class-action–eols-301173141.html

SOURCE Rosen Law Firm, P.A.

November 14, 2020 3:23 pm

ROSEN, GLOBAL INVESTOR COUNSEL, Reminds Tactile Systems Technology, Inc. Investors of Important November 30 Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact the Firm – TCMD

PR Newswire

NEW YORK, Nov. 14, 2020 /PRNewswire/ — Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Tactile Systems Technology, Inc. (NASDAQ: TCMD) between May 7, 2018 and June 8, 2020, inclusive (the “Class Period”), of the important November 30, 2020 lead plaintiff deadline in the securities class action. The lawsuit seeks to recover damages for Tactile investors under the federal securities laws.

To join the Tactile class action, go to http://www.rosenlegal.com/cases-register-1872.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.

According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) while Tactile publicly touted a $4 plus billion or $5 plus billion market opportunity, in truth, the total addressable market for Tactile’s medical devices was materially smaller; (2) to induce sales growth and share gains, Tactile engaged in illegal sales and marketing activities; (3) Tactile’s revenues were in part the product of unlawful conduct and thus unsustainable; and (4) as a result, defendants’ public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than November 30, 2020. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://www.rosenlegal.com/cases-register-1872.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at [email protected] or [email protected].

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Contact Information:

View original content to download multimedia:http://www.prnewswire.com/news-releases/rosen-global-investor-counsel-reminds-tactile-systems-technology-inc-investors-of-important-november-30-deadline-in-securities-class-action-encourages-investors-with-losses-in-excess-of-100k-to-contact-the-firm–tcmd-301173137.html

SOURCE Rosen Law Firm, P.A.

November 14, 2020 3:23 pm

ROSEN, A LEADING AND RESPECTED LAW FIRM, Reminds Teva Pharmaceuticals Industries Limited Investors of the Important November 23 Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $500K to Contact the Firm – TEVA

PR Newswire

NEW YORK, Nov. 14, 2020 /PRNewswire/ — Rosen Law Firm, a global investor rights law firm, reminds the purchasers of the securities of Teva Pharmaceuticals Industries Limited (NYSE: TEVA) between October 29, 2015 and August 18, 2020, inclusive (the “Class Period”), of the important November 23, 2020 lead plaintiff deadline in securities class action. The lawsuit seeks to recover damages for Teva investors under the federal securities laws.

To join the Teva class action, go to http://www.rosenlegal.com/cases-register-1956.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.

The complaint alleges that throughout the Class Period, defendants made materially false and misleading statements regarding Teva’s business, operational, and compliance policies. Specifically, defendants made false and/or misleading statements and/or failed to disclose that: (1) Teva had made substantial illegal kickback payments to charitable foundations to cover Medicare co-payment obligations of patients taking Copaxone; (2) accordingly, Teva’s revenues derived from Copaxone were in part the product of unlawful conduct and thus unsustainable; (3) the foregoing misconduct subjected Teva to a foreseeable risk of heightened regulatory scrutiny and enforcement, as well as reputational harm when the truth became known; and (4) as a result, defendants’ public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than November 23, 2020. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://www.rosenlegal.com/cases-register-1956.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at [email protected] or [email protected].

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Contact Information:

View original content to download multimedia:http://www.prnewswire.com/news-releases/rosen-a-leading-and-respected-law-firm-reminds-teva-pharmaceuticals-industries-limited-investors-of-the-important-november-23-deadline-in-securities-class-action-encourages-investors-with-losses-in-excess-of-500k-to-contact-th-301173135.html

SOURCE Rosen Law Firm, P.A.

November 14, 2020 3:03 pm

ROSEN, A TOP RANKED LAW FIRM, Reminds Pintec Technology Holdings Limited Investors of Important November 30 Deadline in Securities Class Action – PT

PR Newswire

NEW YORK, Nov. 14, 2020 /PRNewswire/ — Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Pintec Technology Holdings Limited (NASDAQ: PT) pursuant and/or traceable to the registration statement issued in connection with Pintec’s October 2018 initial public offering (the “IPO”), of the important November 30, 2020 lead plaintiff deadline in the securities class action. The lawsuit seeks to recover damages for Pintec investors under the federal securities laws.

To join the Pintec class action, go to http://www.rosenlegal.com/cases-register-1608.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.

According to the lawsuit, the registration statement was false and misleading and omitted to state material facts. Specifically, defendants failed to disclose to investors that: (1) Pintec erroneously recorded revenue earned from certain technical service fees on a net basis, rather than a gross basis; (2) there were material weaknesses in Pintec’s internal control over financial reporting related to cash advances outside the normal course of business to Jimu Group, a related party, and to a non-routine loan financing transaction with a third-party entity, Plutux Labs; (3) as a result of the foregoing, Pintec’s financial results for fiscal 2017 and 2018 had been misstated; and (4) as a result of the foregoing, defendants’ positive statements about Pintec’s business, operations, and prospects, were materially misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than November 30, 2020. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://www.rosenlegal.com/cases-register-1608.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at [email protected] or [email protected].

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Contact Information:

View original content to download multimedia:http://www.prnewswire.com/news-releases/rosen-a-top-ranked-law-firm-reminds-pintec-technology-holdings-limited-investors-of-important-november-30-deadline-in-securities-class-action–pt-301173139.html

SOURCE Rosen Law Firm, P.A.

November 14, 2020 3:03 pm

ROSEN, GLOBAL INVESTOR COUNSEL, Files First Securities Class Action Lawsuit Against Biogen Inc.; Encourages Investors with Losses in Excess of $500K to Contact the Firm – BIIB

NEW YORK, Nov. 14, 2020 (GLOBE NEWSWIRE) — Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of the securities of Biogen Inc. (NASDAQ: BIIB), between October 22, 2019 and November 6, 2020, inclusive (the “Class Period”). The lawsuit seeks to recover damages for Biogen investors under the federal securities laws.

To join the Biogen class action, go to http://www.rosenlegal.com/cas e s-register-1981.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.

According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) the larger dataset did not provide necessary data regarding aducanumab’s effectiveness; (2) the EMERGE study did not and would not provide necessary data regarding aducanumab’s effectiveness; (3) the PRIME study did not and would not provide necessary data regarding aducanumab’s effectiveness; (4) the data provided by the Company to the FDA’s Peripheral and Central Nervous System Drugs Advisory Committee did not support finding efficacy of aducanumab; and (5) as a result, defendants’ statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than January 12, 2021. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://www.rosenlegal.com/cases-register-19 8 1.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at [email protected] or [email protected].

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm.

——————————-

Contact Information:

        Laurence Rosen, Esq.
        Phillip Kim, Esq.
        The Rosen Law Firm, P.A.
        275 Madison Avenue, 40^th Floor
        New York, NY 10016
        Tel: (212) 686-1060
        Toll Free: (866) 767-3653
        Fax: (212) 202-3827
        [email protected]
        [email protected]
        [email protected]
        www.rosenlegal.com

November 14, 2020 2:54 pm

ROSEN, RESPECTED INVESTOR COUNSEL, Announces Filing of Securities Class Action Lawsuit Against Intercept Pharmaceuticals, Inc.; Encourages Investors with Losses in Excess of $100K to Contact Firm – ICPT

PR Newswire

NEW YORK, Nov. 14, 2020 /PRNewswire/ — Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT) between September 28, 2019 and October 7, 2020, inclusive (the “Class Period”). The lawsuit seeks to recover damages for Intercept investors under the federal securities laws.

To join the Intercept class action, go to http://www.rosenlegal.com/cases-register-1973.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.

According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) defendants downplayed the true scope and severity of safety concerns associated with Ocaliva’s (obeticholic acid (“OCA”)) use in treating primary biliary cholangitis; (2) the foregoing increased the likelihood of an FDA investigation into Ocaliva’s development, thereby jeopardizing Ocaliva’s continued marketability and the sustainability of its sales; (3) any purported benefits associated with OCA’s efficacy in treating nonalcoholic steatohepatitis (“NASH”) were outweighed by the risks of its use; (4) as a result, the FDA was unlikely to approve Intercept’s New Drug Application for OCA in treating patients with liver fibrosis due to NASH; and (5) as a result of the foregoing, defendants’ positive statements about Intercept’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than January 4, 2021. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://www.rosenlegal.com/cases-register-1973.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at [email protected] or [email protected].

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Contact Information:

View original content to download multimedia:http://www.prnewswire.com/news-releases/rosen-respected-investor-counsel-announces-filing-of-securities-class-action-lawsuit-against-intercept-pharmaceuticals-inc-encourages-investors-with-losses-in-excess-of-100k-to-contact-firm–icpt-301173138.html

SOURCE Rosen Law Firm, P.A.

November 14, 2020 2:33 pm

ROSEN, NATIONAL TRIAL LAWYERS, Reminds First American Financial Corp. Investors of Important December 24 Deadline in First Filed Securities Class Action Commenced by the Firm – FAF

PR Newswire

NEW YORK, Nov. 14, 2020 /PRNewswire/ — Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of First American Financial Corp. (NYSE: FAF) between February 17, 2017 and October 22, 2020, inclusive (the “Class Period”), of the important December 24, 2020 lead plaintiff deadline in the securities class action commenced by the firm. The lawsuit seeks to recover damages for First American investors under the federal securities laws.

To join the First American class action, go to http://www.rosenlegal.com/cases-register-1662.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.

According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) First American failed to implement basic security standards to protect its customers’ sensitive personal information and data; (2) First American faced a heightened risk of cybersecurity failure due to its automation and efficiency initiatives; and (3) as a result, defendants’ public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than December 24, 2020. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://www.rosenlegal.com/cases-register-1662.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at [email protected] or [email protected].

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm.

——————————-

Contact Information:

      Laurence Rosen, Esq.
      Phillip Kim, Esq.
      The Rosen Law Firm, P.A.
      275 Madison Avenue, 40^th Floor
      New York, NY 10016
      Tel: (212) 686-1060
      Toll Free: (866) 767-3653
      Fax: (212) 202-3827
      [email protected]
      [email protected]
      [email protected]
      www.rosenlegal.com

View original content to download multimedia:http://www.prnewswire.com/news-releases/rosen-national-trial-lawyers-reminds-first-american-financial-corp-investors-of-important-december-24-deadline-in-first-filed-securities-class-action-commenced-by-the-firm–faf-301173131.html

SOURCE Rosen Law Firm, P.A.

November 14, 2020 2:33 pm

ROSEN, TOP RANKED INVESTOR COUNSEL, Reminds GoHealth, Inc. Investors of Important November 20 Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact the Firm – GOCO

NEW YORK, Nov. 14, 2020 (GLOBE NEWSWIRE) — Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of GoHealth, Inc. (NASDAQ: GOCO) pursuant and/or traceable to the registration statement issued in connection with GoHealth’s July 2020 initial public offering (the “IPO”) of the important November 20, 2020 lead plaintiff deadline in the case. The lawsuit seeks to recover damages for GoHealth investors under the federal securities laws.

To join the GoHealth class action, go to http://www.rosenlegal.com /cases-register-1939.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.

According to the lawsuit, the registration statement was negligently prepared and failed to disclose that at the time of the IPO: (1) the Medicare insurance industry was undergoing a period of elevated churn, which had begun in the first half of 2020; (2) GoHealth suffered from a higher risk of customer churn as a result of its unique business model and limited carrier base; (3) GoHealth suffered from degradations in customer persistency and retention as a result of elevated industry churn, vulnerabilities that arose from the Company’s concentrated carrier business model, and GoHealth’s efforts to expand into new geographies, develop new carrier partnerships and worsening product mix; (4) GoHealth had entered into materially less favorable revenue sharing arrangements with its external sales agents; and (5) these adverse financial and operational trends were internally projected by GoHealth to continue and worsen following the IPO. When the true details entered the market, the lawsuit claims that investors suffered damages.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than November 20, 2020. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://www.rosenlegal.com/cases-register-19 3 9.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at [email protected] or [email protected].

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

——————————-

Contact Information:

        Laurence Rosen, Esq.
        Phillip Kim, Esq.
        The Rosen Law Firm, P.A.
        275 Madison Avenue, 40th Floor
        New York, NY 10016
        Tel: (212) 686-1060
        Toll Free: (866) 767-3653
        Fax: (212) 202-3827
        [email protected]
        [email protected]
        [email protected]
        www.rosenlegal.com

November 14, 2020 2:03 pm

ROSEN, A LEADING AND LONGSTANDING LAW FIRM, Reminds NextCure, Inc. Investors of Important November 20 Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact Firm – NXTC

PR Newswire

NEW YORK, Nov. 14, 2020 /PRNewswire/ — Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of NextCure, Inc. (NASDAQ: NXTC): (1) between November 5, 2019 and July 14, 2020, inclusive (the “Class Period”); and/or (2) pursuant or traceable to NextCure’s November 2019 secondary public offering of the important November 20, 2020 lead plaintiff deadline in securities class action. The lawsuit seeks to recover damages for NextCure investors under the federal securities laws.

To join the NextCure class action, go to http://www.rosenlegal.com/cases-register-1952.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.

According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose to investors that: (1) NextCure possessed NC318 data that showed a lack of efficacy and objective responses; (2) NC318 was not, in fact, effective in treating most tumor types; (3) the NC318 application was proving to be limited (if even useful at all); (4) as a result of the foregoing, there was a significant realizable risk that NC318 would not be nearly as popular as then-existing blockbuster drugs, such as Keytruda; and (5) as a result, defendants’ public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than November 20, 2020. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://www.rosenlegal.com/cases-register-1952.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at [email protected] or [email protected].

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

——————————-

Contact Information:

View original content:http://www.prnewswire.com/news-releases/rosen-a-leading-and-longstanding-law-firm-reminds-nextcure-inc-investors-of-important-november-20-deadline-in-securities-class-action-encourages-investors-with-losses-in-excess-of-100k-to-contact-firm–nxtc-301173128.html

SOURCE Rosen Law Firm, P.A.